Bristol-Myers Squibb Company

$ 44.62 0 (0%)
Volume: 14,961,300 Avg Vol (1m): 18,744,470
Market Cap $: 72.91 Bil Enterprise Value $: 71.47 Bil
P/E (TTM): 14.73 P/B: 5.19
Earnings Power Value 7.71
Net Current Asset Value -2.32
Tangible Book 3.92
Projected FCF 25.77
Median P/S Value 56.78
Graham Number 16.35
Peter Lynch Value 50.27
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

Current vs industry vs history
Cash-to-Debt 1.21
Equity-to-Asset 0.40
Debt-to-Equity 0.52
Debt-to-EBITDA 1.08
Interest Coverage 28.11
Piotroski F-Score 9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.94
DISTRESS
GREY
SAFE
Beneish M-Score -2.67
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 31.65%
WACC 7.17%

Profitability & Growth : 9/10

Current vs industry vs history
Operating Margin % 22.80
Net Margin % 21.81
ROE % 38.13
ROA % 14.64
ROC (Joel Greenblatt) % 121.75
3-Year Total Revenue Growth Rate 10.90
3-Year Total EBITDA Growth Rate 37.00
3-Year EPS w/o NRI Growth Rate 47.90

» BMY's 30-Y Financials

Financials (Next Earnings Date: 2019-04-25)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:BMY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare LSE:AZN NYSE:LLY XPAR:SAN LSE:GSK XTER:BAYN TSE:4503 TSE:4519 TSE:4578 TSE:4568 HKSE:01093 NYSE:ABBV TSE:4151 TSE:4528 NYSE:MRK SHSE:600436 SHSE:600867 SZSE:002422 MIL:REC BOM:500087 BOM:500302
Traded in other countries BMYB34.Brazil BRM.Germany 0R1F.UK
Address 430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Ratios

Current vs industry vs history
PE Ratio (TTM) 14.73
Forward PE Ratio 10.87
N/A
PE Ratio without NRI 14.73
Price-to-Owner-Earnings 14.44
PB Ratio 5.19
PS Ratio 3.24
Price-to-Free-Cash-Flow 14.65
Price-to-Operating-Cash-Flow 12.28
EV-to-EBIT 11.61
EV-to-EBITDA 10.56
EV-to-Revenue 3.17
PEG Ratio 0.82
Shiller PE Ratio 18.41
Current Ratio 1.61
Quick Ratio 1.50
Days Inventory 68.19
Days Sales Outstanding 75.00
Days Payable 105.48

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 3.63
Dividend Payout Ratio 0.53
3-Year Dividend Growth Rate (Per Share) 2.60
Forward Dividend Yield % 3.62
N/A
Yield-on-Cost (5-Year) % 4.15
3-Year Share Buyback Rate 0.60

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 11.38
Price-to-Projected-FCF 1.73
Price-to-Median-PS-Value 0.79
Price-to-Peter-Lynch-Fair-Value 0.89
Price-to-Graham-Number 2.73
Earnings Yield (Joel Greenblatt) % 8.60
Forward Rate of Return (Yacktman) % 20.57

More Statistics

Revenue (TTM) (Mil) $ 22,561
EPS (TTM) $ 3.03
Beta 0.87
Volatility % 29.61
52-Week Range $ 44.3 - 63.69
Shares Outstanding (Mil) 1,633.96

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 9
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y